Acute lymphoblastic leukemia: past and present

Česká verzia

Authors: C. Šálek; D. Šponerová; J. Soukupová Maaloufová
Authors place of work: Ústav hematologie a krevní transfuze Praha, ředitel prof. MUDr. Marek Trněný, CSc.
Published in the journal: Vnitř Lék 2012; 58(Suppl 2): 20-26
Category:

Summary

Acute lymphoblastic leukemia (ALL) is a rare neoplasm in adults. Its treatment has seen dynamic developments ranging from the discovery of first compounds with cytostatic effect through to the introduction of multicomponent chemotherapy, incorporation of hematopoietic stem cell transplantation into postconsolidation therapy as well as dose intensity adjustment according to defined risk groups. The basic therapeutical principle of present treatment strategies is an individualised approach. Modern protocols build on the prognostic significance of minimal residual disease and incorporate new drugs such as tyrosine kinase inhibitors, monoclonal antibodies or new forms of non-genotoxic drugs, for specific ALL subgroups. Long-term survival has significantly improved from < 1% 60 years ago to ~ 40% at present.

Key words:
acute lymphoblastic leukemia – risk factors – minimal residual disease – therapy – hematopoetic stem cell transplantation – history of UHKT

Zdroje

1. Dores GM, Devesa SS, Curtis RE et al. Acute leukemia incidence and patient survival among children and adults in the United States, 2001–2007. Blood 2012; 119: 34–43.

2. Seibel NL. Acute lymphoblastic leukemia: an historical perspective. Hematology Am Soc Hematol Educ Program 2008: 365.

3. Rowe JM, Buck G, Burnett AK et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1,500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood 2005; 106: 3760–3767.

4. Annino L, Vegna ML, Camera A et al. Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood 2002; 99: 863–871.

5. Marks DI, Paietta EM, Moorman AV et al. T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993). Blood 2009; 114: 5136–5145.

6. Moorman AV, Harrison CJ, Buck GA et al. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2,993 trial. Blood 2007; 109: 3189–3197.

7. Bassan R, Spinelli O, Oldani E et al. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood 2009; 113: 4153–4162.

8. Brüggemann M, Raff T, Flohr T et al. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood 2006; 107: 1116–1123.

9. Campana D, Pui CH. Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance. Blood 1995; 85: 1416–1434.

10. van der Velden VH, Willemse MJ, van der Schoot CE et al. Immunoglobulin kappa deleting element rearrangements in precursor-B acute lymphoblastic leukemia are stable targets for detection of minimal residual disease by real-time quantitative PCR. Leukemia 2002; 16: 928–936.

11. van der Velden VH, Wijkhuijs JM, Jacobs DC et al. T cell receptor gamma gene rearrangements as targets for detection of minimal residual disease in acute lymphoblastic leukemia by real-time quantitative PCR analysis. Leukemia 2002; 16: 1372–1380.

12. van der Velden VH, Cazzaniga G, Schrauder A et al. Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia 2007; 21: 604–611.

13. Brüggemann M, Schrauder A, Raff T et al. Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18.–20. September 2008. Leukemia 2010; 24: 521–535.

14. Dworzak MN, Gaipa G, Ratei R et al. Standardization of flow cytometric minimal residual disease evaluation in acute lymphoblastic leukemia: Multicentric assessment is feasible. Cytometry B Clin Cytom 2008; 74: 331–340.

15. Bassan R, Hoelzer D. Modern therapy of acute lymphoblastic leukemia. J Clin Oncol 2011; 29: 532–543.

16. Thomas ED, Buckner CD, Clift RA et al. Marrow transplantation for acute nonlymphoblastic leukemia in first remission. N Engl J Med 1979; 301: 597–599.

17. Goldstone AH, Richards SM, Lazarus HM et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the international ALL trial (MRC UKALL XII/ECOG E2993). Blood 2008; 111: 1827–1833.

18. Hahn T, Wall D, Camitta B et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in adults: an evidence-based review. Biol Blood Marrow Transplant 2006; 12: 1–30.

19. Ram R, Wolach O, Vidal L et al. Adolescents and young adults with acute lymphoblastic leukemia have a better outcome when treated with pediatric-inspired regimens: systematic review and meta-analysis. Am J Hematol 2012; 87: 472–478.

20. Giebel S, Stella-Holowiecka B, Krawczyk-Kulis M et al. Status of minimal residual disease determines outcome of autologous hematopoietic SCT in adult ALL. Bone Marrow Transplant 2010; 45: 1095–1101.

21. Ribera JM, Oriol A, González M et al. Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial. Haematologica 2010; 95: 87–95.

22. Bassan R, Rossi G, Pogliani EM et al. Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00. J Clin Oncol 2010; 28: 3644–3652.

23. Fielding AK, Rowe JM, Richards SM et al. Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the international ALL Trial MRC UKALLXII/ECOG2993. Blood 2009; 113: 4489–4496.

24. Vignetti M, Fazi P, Cimino G et al. Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA) LAL0201-B protocol. Blood 2007; 109: 3676–3678.

25. Ravandi F, O’Brien S, Jorgensen J et al. Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia. Blood 2011; 118: 3818–3823.

26. Pfeifer H, Lange T, Wystub S et al. Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia. Leukemia 2012; 26: 1475–1481.

27. Hoelzer D, Gökbuget N. Chemoimmunotherapy in acute lymphoblastic leukemia. Blood Rev 2012; 26: 25–32.

28. Topp MS, Kufer P, Gökbuget N et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 2011; 29: 2493–2498.

29. Gökbuget N, Basara N, Baurmann H et al. High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation. Blood 2011; 118: 3504–3511.

30. Fière D, Marty M, Solal-Celigny P et al. Intensive induction and early consolidation of acute lymphoid leukemia in the adult. A pilot study of feasibility and long-term development. Presse Med 1989; 18: 221–223.

31. Thomas X, Boiron JM, Huguet F et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol 2004; 22: 4075–4086.

32. Linker C, Damon L, Ries C et al. Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia. J Clin Oncol 2002; 20: 2464–2471.

33. European Leukemia Net. European Leukemia Trial Registry – Trial: ALL GMALL 07/2003. Available from: http://www.leukemia-net.org/trial/download/public/ALL_GMALL07-03.